{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:30:06Z","timestamp":1764937806312,"version":"3.41.2"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The exact mechanism of hyperammonemia is thought to be multifactorial, but is not yet fully understood. No studies have yet reported hyperammonemia combined with Fanconi syndrome caused by deferasirox.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 10-year-old girl was admitted for vomiting and altered consciousness. Blood testing revealed hyperammonemia and normal liver and coagulation functions. During hospitalization, the patient also exhibited hyperchloremic metabolic acidosis, hypokalemia, hyponatremia, and hypophosphatemia. Additionally, urinalysis revealed glucose and protein levels clinically consistent with Fanconi syndrome. The patient had a history of severe beta-thalassemia and had received intermittent blood transfusions for approximately ten years. The patient had been administered oral deferasirox at a 400\u2005mg\/day dose at the age of four, which had been gradually increased to the current 750\u2005mg\/day dosage. Upon admission, deferasirox was discontinued and treatment including mechanical ventilation, continuous blood purification therapy for ammonia reduction and acidosis, and electrolyte imbalance corrections was administered. Subsequently, serological markers returned to normal, urine test findings improved. To the best of our knowledge, this is the first report of a case of hyperammonemia with Fanconi syndrome owing to deferasirox.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>For effective management and long-term follow-up of chronic diseases in children, pediatricians must master standardized treatments and the adverse reactions of various drugs. When symptoms are difficult to explain clinically, we must trace the source and adjust the treatment plan to maximize improving the patient's prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1461867","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T09:53:13Z","timestamp":1728553993000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Deferasirox-induced hyperammonemia and Fanconi syndrome: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Houfu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoxue","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.2169\/internalmedicine.0922-22","article-title":"Hyperammonemia due to empyema","volume":"62","author":"Wada","year":"2023","journal-title":"Intern Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00467-011-1838-5","article-title":"Hyperammonemia in review: pathophysiology, diagnosis, and treatment","volume":"27","author":"Auron","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/vox.13064","article-title":"Deferasirox-associated fanconi syndrome in adult patients with transfusional iron overload","volume":"116","author":"Yui","year":"2021","journal-title":"Vox Sang"},{"key":"B4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41581-020-0267-8","article-title":"Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy","volume":"16","author":"Raina","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/jcp-2022-208644","article-title":"Drug-induced hyperammonaemia","volume":"76","author":"Shakerdi","year":"2023","journal-title":"J Clin Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.7326\/L17-0641","article-title":"Hyperammonemia after blood transfusion","volume":"168","author":"Rossfeld","year":"2018","journal-title":"Ann Intern Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/15563650.2018.1523425","article-title":"Acute hyperammonemia in children under deferasirox treatment: cutting the Gordian knot","volume":"57","author":"Martinelli","year":"2019","journal-title":"Clin Toxicol (Phila)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00228-015-1956-2","article-title":"Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis","volume":"72","author":"Marano","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2352-4642(18)30335-3","article-title":"Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies","volume":"3","author":"Bird","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/bjh.13002","article-title":"Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia","volume":"167","author":"Dee","year":"2014","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1365-2141.2009.07908.x","article-title":"Efficacy and safety of deferasirox doses of >30\u2005mg\/kg per d in patients with transfusion-dependent anaemia and iron overload","volume":"147","author":"Taher","year":"2009","journal-title":"Br J Haematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/liv.12221","article-title":"Ammonia clearance with haemofiltration in adults with liver disease","volume":"34","author":"Slack","year":"2014","journal-title":"Liver Int"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1461867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T09:53:15Z","timestamp":1728553995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1461867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":13,"alternative-id":["10.3389\/fped.2024.1461867"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1461867","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"article-number":"1461867"}}